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Abstract
Background: Hyperhomocysteinemia has been identified as a potential risk for atherosclerotic
disease in epidemiologic studies. This study investigates the impact of elevated serum homocysteine
on restenosis after carotid endarterectomy (CEA).
Methods: In a retrospective study, we compared fasting plasma homocysteine levels of 51 patients
who developed restenosis during an eight year period after CEA with 45 patients who did not
develop restenosis. Restenosis was defined as at least 50% stenosis and was assessed by applying a
routine duplex scan follow up investigation. Patients with restenosis were divided into a group with
early restenosis (between 3 and 18 months postoperative, a total of 39 patients) and late restenosis
(19 and more months; a total of 12 patients).
Results: The groups were controlled for age, sex, and risk factors such as diabetes, nicotine abuse,
weight, hypertension, and hyperlipidemia. Patients with restenosis had a significant lower mean
homocysteine level (9.11 µmol/L; range: 3.23 µmol/L to 26.49 µmol/L) compared to patients
without restenosis (11.01 µmol/L; range: 5.09 µmol/L to 23.29 µmol/L; p = 0.03).
Mean homocysteine level in patients with early restenosis was 8.88 µmol/L (range: 3.23–26.49
µmol/L) and 9.86 µmol/L (range 4.44–19.06 µmol/L) in late restenosis (p = 0.50).
Conclusion: The finding suggests that high plasma homocysteine concentrations do not play a
significant role in the development of restenosis following CEA.
Background
Compared to the best medical therapy, carotid endarterec-
tomy (CEA) or eversions-endarteriectomy has been iden-
tified as preferred treatment for symptomatic and
asymptomatic patients with high-grade extra cranial
carotid stenosis [1].
The long term follow-up of such patients indicates how-
ever, that a recurrent stenosis may occur in up to 36% of
patients [2], but the incidence of carotid restenosis (CR) is
variable and in part dependent on the definition of reste-
nosis and the technique used to calculate its incidence.
Symptomatic or asymptomatic CR is generally attributed
to neointimal hyperplasia during the early postoperative
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period (within 36 months) or recurrent atherosclerosis
thereafter [2]. Late CR lesions are indistinguishable from
primary atherosclerosis. Neointimal hyperplasia is an
intensely studied hyperpalstic reaction in the arterial wall.
On gross as well as angiographic or duplex ultrasound
interrogation, neointimal hyperplasia is generally smooth
in appearance. The exact mechanisms for neointimal
hyperplasia are still being investigated, but homocysteine
seems to contribute to increased neointimal hyperplasia
[3].
Homocysteine is a sulfhydryl amino acid. Its precursor,
the essential amino acid methionine, is derived from die-
tary proteins.
The metabolism of homocysteine stands at the intersec-
tion of two pathways: remethylation to methionine,
which requires folate and vitamin B12 (or betaine in an
alternative reaction); and transsulfuration to cystathio-
nine, which requires pyridoxal-5'-phosphate [4].
Normal levels of Homocysteine are between 5 and 15
µmol/L [5]. There is however, an increased risk for cardio-
vascular diseases with plasma homocysteine concentra-
tions above 10 µmol/L [6]. Plasma levels between 15 and
30 µmol/L are described as mild hyperhomocysteinemia,
levels between 31 and 100 µmol/L are described as mod-
erate and levels above 100 µmol/L are described as severe
hyperhomocysteinemia.
Mild hyperhomocysteinemia in fasting conditions can be
attributed to any of the following factors: mild impair-
ment in the methylation pathway (i.e. folate or vitamin
B12 deficiencies or methylenetetrahydrofolate reductase
(MTHFR) thermolability), heterozygous cystathionine
beta-synthase defect, vitamin B6 deficiency, or due to
smoking, nutritional, hormonal and pharmacological fac-
tors [7,8]. In addition, pathologic states (e.g. renal insuffi-
ciency, breast, ovarian and pancreatic cancers, and
lymphoblastic leukaemia) elevate plasma homocysteine
levels [9].
Severe hyperhomocysteinemia is due to rare genetic
defects resulting in deficiencies in cystathionine beta syn-
thase, MTHFR, or in enzymes involved in methyl-B12 syn-
thesis and homocysteine methylation [10].
An association between the plasma homocysteine concen-
tration and arteriosclerosis has become the subject of
many clinical studies, which have consistently linked
moderate hyperhomocysteinemia to symptomatic
peripheral vascular, cerebrovascular, and coronary heart
disease [11].
The mechanism by which hyperhomocysteinemia causes
endothelial damage is not known. Early studies with non-
physiological high homocysteine levels showed a variety
of deleterious effects on endothelial or smooth muscle
cells in culture [12].
The damaging effect may be related to oxidative stress
because reactive oxygen species are produced during the
auto oxidation of homocysteine [13]. Free radicals induce
lipid per oxidation, oxidation of LDL and further intracel-
lular accumulation of cholesterol. Homocysteine
increases proliferation of vascular smooth muscle cells
and inhibits the growth of endothelial cells [14].
It is the focus of this study to investigate whether there is
an association between an elevated plasma homocysteine
level and a restenosis after CEA.
Methods
Routine duplex scan following CEA identified a total of 51
CR patients in the author's hospital (University of Ulm,
Department of Vascular Surgery; Germany) that were
operated on internal carotid stenosis between 1995 and
2003. As criteria for inclusion in the CR group, patients
had at least 50% stenosis but no stenosis within the first
three months after operation. 45 patients who did not
show CR in a 2 year period after CEA formed a compara-
tive group. All patients were subjected to a postoperative
Doppler examination and the postoperative results were
recorded. All patients received a thrombocyte aggregation
inhibitor or an anticoagulative medication.
Fasting blood samples were taken from each patient at a
follow up investigation. Blood was immediately centri-
fuged (10 minutes, 3000 rpm, 4°C) and plasma samples
were stored at -80°C. A fully automated immunoassay for
total plasma homocysteine was used to determine the
fasting homocysteine level. Furthermore, patients were
examined regarding atherosclerosis risk factors (hyperten-
sion, diabetes, hypercholesterolemia, nicotine abuse, adi-
posities) as well as use of medication was recorded.
Approval for the study was obtained from the ethical com-
mittee of the University of Ulm. Written informed consent
was obtained from all patients before examination.
Patients were subjected to a Duplex examination of the
carotid arteries with a high-resolution, real time scanner
equipped with a 7.5 MHz imaging transducer, a 4 MHz
pulse-wave Doppler transducer, and a 4 MHz continuous-
wave transducer.
In the following result section, results are shown as abso-
lute values, and when appropriate as percentage, mean,
median, and range. Values between groups are comparedBMC Cardiovascular Disorders 2008, 8:1 http://www.biomedcentral.com/1471-2261/8/1
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through application of a two sided Student's t-test. A dif-
ference was considered significant at the 0.05 level.
Results
A. Patients
The CR group consists of 51 patients of which 33 (65%)
were male and 18 (35%) female. Median age was 69 years
(range: 50 and 87). With these patients, CR was diagnosed
between 3 and 74 months (median 10 months) after CEA.
The comparative group consists of 45 patients of which 38
(84%) were male and 7 (16%) female with a median age
of 70 years (range: 50 and 83 years). The postoperative
restenosis free period ranged between 24 and 108 months
(median 42 months).
Postoperative medication with a thrombocyte aggregation
inhibitor or an anticoaguative medication was similar in
both groups. In the CR group, 48 out of 51 (94%) patients
took acetylsalicylate (Aspirin®) or clopidogrel bisulfate
(PLAVIX®) or both. The remaining 3 (6%) patients took
an anticoagulative medication like cumarine (Marcur-
mar®). In the comparative group, 43 out of 45 (96%)
patients took thrombocyte aggregation inhibitor. The
remaining 2 (4%) patients took anticoagulative medica-
tion. Participants of the study were asked for regularly
vitamin/folate intake. Only one patient with carotid rest-
enosis took vitamin B regularly.
B. Restenosis
In most cases, CR occurred within the first twelve months
(31 out of 51 patients; 61%). After additional 12 months,
CR was diagnosed in 45 patients (88%). Only 6 patients
(12%) developed CR later than 2 years after CEA. As
described above, CR group was divided into a subgroup
with early restenosis (3 to 18 months; 39 patients) and a
subgroup with late restenosis (19 and more months; 12
patients). This is graphically shown in Figure 1.
C. Homocysteine concentrations
Mean homocysteine score for homocysteine levels for the
entire study group was 10.00 µmol/L whereby levels rage
between 3.23 µmol/L and 26.49 µmol/L (median: 9.10
µmol/L, standard deviation: 4.32 µmol/L). The mean
score of CR group was 9.11 µmol/L, ranging form 3.23
µmol/L to 26.49 µmol/L (median: 7.78 µmol/L; standard
deviation: 4.30 µmol/L). The mean level of comparative
group was 11.01 µmol/L (range: 5.09 µmol/L to 23.29
µmol/L; median: 10.08 µmol/L; standard deviation: 4.16
µmol/L; Figure 2). The homocysteine levels in the CR
group were significant lower compared to the compara-
tive group (p = 0.03).
D. Homocysteine concentration and risk factors
Patients were examined regarding five atherosclerosis risk
factors (hypertension, diabetes, hypercholesterolemia,
nicotine abuse, and adipositas). Examined risk factors
were similar distributed in both groups, as exhibited in
Table 1. Patients of both groups have 2 risk factors on
average (restenosis group 2.0 risk factors; comparative
group 2.04 risk factors). Patients in the restenosis group
with two or less risk factors have an average homocysteine
level of 9.43 µmol/L, patients with three or more risk fac-
tors have an average homocysteine level of 8.34 µmol/L (p
= 0.41). In the comparative group patients with two or less
risk factors have an average homocysteine level of 10.87
µmol/L, patients with three and more have 11.89 µmol/L
(p = 0.52). Consequently, there is no difference of homo-
cysteine level in groups with more or less additional risk
Mean scores of homocysteine levels for all patients, resteno- sis group, and comparative group Figure 2
Mean scores of homocysteine levels for all patients, resteno-
sis group, and comparative group.
Number of patients with carotid restenosis (CR) according  to occurrence in months Figure 1
Number of patients with carotid restenosis (CR) according 
to occurrence in months.BMC Cardiovascular Disorders 2008, 8:1 http://www.biomedcentral.com/1471-2261/8/1
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factors. Likewise no difference was seen comparing count
of risk factors in subgroups with homocysteine level
below 10 µmol/L and above 10 µmol/L (Restenosis group
<10 µmol/L: 2.03 risk factors on average, Restenosis group
>10 µmol/L: 2.03 risk factors on average; Control group
<10 µmol/L: 2.14 risk factors on average, Control group
>10 µmol/L: 1.91 risk factors on average; not significant).
The concentrations of total and free plasma homocysteine
were higher in active smoker [8]. In our study 8 patients
out of 55 with a homocysteine levels below 10 µmol/L
smoke, and 7 patients out of 41 with a homocysteine lev-
els above 10 µmol/L smoke. In contrast to literature, there
was no significant difference in the homocysteine levels of
smokers and non-smokers (9.68 µmol/L, 10.0 µmol/L
respectively). The lack of significant difference between
homocysteine values between smokers versus non-smok-
ers was probably due to the low patient enrolment. Cross-
sectional analysis conducted in recent years confirms the
influence of smoking on homocysteine levels. Some stud-
ies, however, have failed to find any relationship between
smoking and homocysteine levels [15,16]
E. Homocysteine concentration in early and late CR 
patients
Patients with an early CR (3 to 18 months) showed a
mean homocysteine level of 8.88 µmol/L (range: 3.23
µmol/L to 26.49 µmol/L; median: 7.69 µmol/L; standard
deviation: 4.33 µmol/L). Patients with a late CR (more
than 18 months after operation) showed a mean homo-
cysteine level of 9.86 µmol/L (range: 4.44 µmol/L to
19.06 µmol/L; median: 9.72 µmol/L; standard deviation:
4.33 µmol/L). Application of t-test showed no significant
difference in the homocysteine levels in both groups (p =
0.50).
Discussion
Data from several studies suggest a mild plasma hyperho-
mocysteinemia as risk factor for occlusive vascular disease
and a 25% risk factor for prevalence of extra cranial
carotid artery stenosis in both men and women [17]. The
mechanisms by which homocysteine may cause vascular
disease include a propensity for thrombosis and impaired
thrombolysis, increased production of hydrogen perox-
ide, endothelial dysfunction and increased oxidation of
low-density lipoproteins and Lp(a) lipoproteins [14].
The empirical investigation in this study was concerned
with the role of homocysteine in the development of CR.
For that purpose, we compared homocysteine levels in
patients who had not developed CR 24 months or more
after CEA with homocysteine levels in patients who devel-
oped CR after three or more months. Our results suggest
no systematic relationship between elevated homo-
cysteine levels and the occurrence of CR.
Limitations of our study include the lack of data on serum
folate levels, the lack of a genetic analysis regarding
MTHFR, and the fact that we measured fasting homo-
cysteine level only once irrespective of transient fluctua-
tions [18]. Further, the patients were sampled between
one and four years after CEA and not at the same postop-
erative time. As with other studies the comparison of
results between different labs approved troublesome [19].
Our results are in line with other recent studies that also
suggest no systematic relationship between elevated
homocysteine levels and the occurrence of CR.
Assadian et al. evaluated the association of plasma homo-
cysteine with early recurrent carotid stenosis following
carotid eversion endarterectomy. They found no associa-
tion of homocysteine with early restenosis [20].
Samson et al. compared homocysteine levels in patients
who did not developed CR with those who did within 2
years of CEA. In their study the average homocysteine
score for the entire study group was 12.5 µmol/L. The
homocysteine values for the subgroups did not differ sig-
nificantly [21].
Laxdal et al. investigate in a prospective, observational
study the effect of elevated serum homocysteine on the
likelihood to develop CR after CEA. The authors find a sig-
nificant association between homocysteine values within
the lower two thirds of the normal range and the occur-
rence of CR [22].
In contrast to that, Southern et al. find in a rat model
increasing levels of plasma homocysteine to enhance and
accelerated a smooth muscle cell response after CEA lead-
ing to increased intimal hyperplasia and luminal stenosis
Table 1: Distribution of additional risk factors for restenosis group and comparative group.
Risk factor Restenosis group Comparative group
Overweight 7 of 51 (13.7%) 7 of 45 (15.6%)
Diabetes 15 of 51 (29.4%) 14 of 45 (31.1%)
Nicotine 9 of 51 (17.7%) 6 of 45 (13.3%)
Hypertension 42 of 51 (82.4%) 37 of 45 (82.2%)
Hyperlipidemia 29 of 51 (56.9%) 27 of 45 (60.0%)BMC Cardiovascular Disorders 2008, 8:1 http://www.biomedcentral.com/1471-2261/8/1
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[23]. Furthermore, results of a prospective study by Schny-
der indicate that homocysteine levels also can predict
long-term outcome after percutaneous coronary interven-
tion regarding target lesion revascularization [24]. On the
other hand homocysteine did not appear to influence the
outcome of endovascular intervention after endovascular
treatment of the above-knee femoro-popliteal artery [25].
As indicated by the studies above there is no consensus yet
in literature whether elevated plasma levels of homo-
cysteine are an independent risk factor for restenosis.
Studies on biological properties of human endothelial
cells from different types of vasculature and different loca-
tions are warranted, specifically with respect to homo-
cysteine metabolism and its effect. A critical question in
this context is whether the relationship between homo-
cysteine levels and outcomes after vascular intervention is
of causal nature. Plasma homocysteine could also be sig-
nificantly correlated with age, serum creatinine, and HDL
cholesterol, as well as significantly associated with gender
and previous MI [24].
Conclusion
The effects of elevated plasma levels of homocysteine on
the rate of CR are contradicting. Our finding suggests that
high plasma homocysteine concentrations do not play a
significant role in the development of restenosis following
CEA. Additional studies are needed to investigate the
impact of hyperhomocysteinemia on cardiovascular dis-
ease. A critical question in this context is whether the rela-
tionship between homocysteine levels and outcomes after
vascular intervention is of causal nature. Elevated plasma
levels of homocysteine could be a marker, rather than the
cause for the respective disease [17].
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